The last few years have seen a flurry of FDA approvals for AML including a liposomal formulation of daunarubicin and cytarabine, the anti-CD33 antibody drug conjugate gemtuzumab ozogamicin, the IDH1/2 mutant inhibitors ivosidenib and enasidenib, the FLT3-ITD inhibitors midostaurin (in combination with chemotherapy) and gilternitib and the BCL2 inhibitor venetoclax (in combination with HMA or low dose cytarabine). Here, FLT3 is linked to acute myeloid leukemia.